Lonza Group (VTX: LONN), an international pharmaceutical and biotechnology company, plans to open a 100,000-square-foot facility in Pearland.
The facility, which is expected to open in the first half of 2017, will be used to expand the Basel, Switzerland-based company’s gene therapy business, according to a statement. It will more than double Lonza’s production of viral gene and virally modified therapeutics.
